-
公开(公告)号：US20230117803A1
公开(公告)日：2023-04-20
申请号：US17759906
申请日：2021-02-02
Applicant: BIONTECH SE
Inventor： Ugur SAHIN , Alexander MUIK , Lena KRANZ , Mathias VORMEHR
Abstract: The present disclosure relates to methods and compositions for inducing an immune response in a subject comprising providing to the subject a peptide or protein vaccine and a binding agent, such as a bispecific antibody, binding to PD-L1 and CD137, such as human PD-L1 and human CD137, e.g., by co-administering to the subject a peptide or protein used for vaccination or a polynucleotide, in particular RNA, encoding a peptide or protein used for vaccination, and a binding agent binding to PD-L1 and CD137 or a polynucleotide, in particular RNA, encoding a binding agent binding to PD-L1 and CD137. The present disclosure further relates to medical preparations useful in the methods disclosed herein.
-
公开(公告)号：US20210277133A1
公开(公告)日：2021-09-09
申请号：US17172700
申请日：2021-02-10
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20210269541A1
公开(公告)日：2021-09-02
申请号：US17172698
申请日：2021-02-10
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
Patent Agency Ranking
公开(公告)号：US20250002600A1
公开(公告)日：2025-01-02
申请号：US18696689
申请日：2022-10-05
Applicant: Genmab A/S , BioNTech SE
Inventor： Alexander MUIK , Kristina SCHÖDEL , Nora PENCHEVA , Maria N. JURE-KUNKEL , Ugur SAHIN , Sina FELLERMEIER-KOPF , Patricia GARRIDO CASTRO , Jordan BLUM , Friederike GIESEKE , Esther C. W. BREIJ , Lars GUELEN , Joost NEIJSSEN , Karsten BECKMANN , Claudia PAULMANN , Bart-Jan DE KREUK , Richard G. HIBBERT , Janine SCHUURMAN , Aran LABRIJN , Ivan KUZMANOV
Abstract: The present invention provides combination therapy using a binding agent that binds to human CD137 and to human PD-L1 in combination with a PD-1 inhibitor to reduce or prevent progression of a tumor or treating cancer.
-
15.发明公开公开(公告)号：US20230399403A1
公开(公告)日：2023-12-14
申请号：US18035172
申请日：2021-11-11
Applicant: BioNTech SE
Inventor： Ugur SAHIN , Karsten BECKMANN , Claudia PAULMANN , Sina FELLERMEIER-KOPF , Friederike GIESEKE , Alexander MUIK , Ivan KUZMANOV
IPC: C07K16/28 , G01N33/574
CPC classification number: C07K16/2818 , G01N33/57492 , C07K2317/565 , G01N2333/70521 , C07K2317/92 , C07K2317/76 , C07K2317/24
Abstract: The present disclosure relates to antibodies having the ability of binding to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody having the ability of binding to the immune checkpoint protein PD-1, such as human PD-1, or a nucleic acid encoding such an antibody, or a composition comprising said antibody or nucleic acid.
-
公开(公告)号：US20230087745A1
公开(公告)日：2023-03-23
申请号：US17821837
申请日：2022-08-24
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ , Edward VAN DEN BRINK , Dennis VERZIJL
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20230087164A1
公开(公告)日：2023-03-23
申请号：US17795318
申请日：2021-02-04
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Ugur SAHIN , Alexander MUIK , Isil ALTINTAS , Ulf FORSSMANN , Kate SASSER , Maria JURE-KUNKEL , Manish GUPTA
Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer. The method comprises administering to a subject, a binding agent comprising a first binding region binding to human CD137 and a second binding region binding to human PD-L1. The amount of binding agent administered in each treatment cycle is preferably about 0.3-5 mg/kg body weight or about 25-400 mg in total.
-
公开(公告)号：US20210369842A1
公开(公告)日：2021-12-02
申请号：US17289602
申请日：2019-11-06
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK
Abstract: The present invention relates to pharmaceutical formulations of binding agents and their use in medicine. In particular, the invention relates to pharmaceutical formulations of binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the pharmaceutical formulations of the invention and to methods for producing pharmaceutical formulations.
-
-
-
-
-
-
-
Search Results
18
records
(took 0.016 seconds)
